Literature DB >> 11937181

Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study.

Quanhe Yang1, Sonja A Rasmussen, J M Friedman.   

Abstract

BACKGROUND: Down's syndrome is the most frequently identified cause of mental retardation, but information about mortality and comorbidity in people with Down's syndrome is limited.
METHODS: We used data from US death certificates from 1983 to 1997 to calculate median age at death and standardised mortality odds ratios (SMORs) for common medical disorders in people with Down's syndrome.
FINDINGS: Of 17897 people reported to have Down's syndrome, median age at death increased from 25 years in 1983 to 49 years in 1997, an average increase of 1.7 years per year studied (p<0.0001). Median age at death was significantly lower in black people and people of other races than in white people with Down's syndrome. As expected, death certificates with a diagnosis of Down's syndrome were more likely to list congenital heart defects (SMOR 29.1, 95% CI 27.8-30.4), dementia (21.2, 19.6-22.7), hypothyroidism (20.3, 18.5-22.3), or leukaemia (1.6, 1.4-1.8) than were those that did not report Down's syndrome. By contrast, malignant neoplasms other than leukaemia were listed on death certificates of people with Down's syndrome less than one-tenth as often as expected (0.07, 0.06-0.08). A strikingly low SMOR for malignancy was associated with Down's syndrome at all ages, in both sexes, and for all common tumour types except leukaemia and testicular cancer.
INTERPRETATION: Identification of factors responsible for the racial differences recorded could facilitate further improvement in survival of people with Down's syndrome. Reduced exposure to environmental factors that contribute to cancer risk, tumour-suppressor genes on chromosome 21, or a slower rate of replication or higher likelihood of apoptosis in Down's syndrome cells, could be possible reasons for paucity of cancer in people with Down's syndrome.

Entities:  

Mesh:

Year:  2002        PMID: 11937181     DOI: 10.1016/s0140-6736(02)08092-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  168 in total

Review 1.  Trisomy 21 and early brain development.

Authors:  Tarik F Haydar; Roger H Reeves
Journal:  Trends Neurosci       Date:  2011-12-09       Impact factor: 13.837

2.  Trisomy-21 gene dosage over-expression of miRNAs results in the haploinsufficiency of specific target proteins.

Authors:  Terry S Elton; Sarah E Sansom; Mickey M Martin
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

3.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

4.  DS-Connect: A Promising Tool to Improve Lives and Engage Down Syndrome Communities Worldwide.

Authors:  Emmanuel K Peprah; Melissa A Parisi; Lisa Kaeser; Sujata Bardhan; MaryLou Oster-Granite; Yvonne T Maddox
Journal:  Glob Heart       Date:  2015-08-11

5.  Increasing total prevalence rate of cases with Down syndrome in Hungary.

Authors:  Julia Métneki; Andrew E Czeizel
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

6.  Birth defects and disabilities: a public health issue for the 21st century.

Authors:  Coleen A Boyle; José F Cordero
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

7.  Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.

Authors:  Eleonore Bayen; Katherine L Possin; Yingjia Chen; Laurent Cleret de Langavant; Kristine Yaffe
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

Review 8.  Malignancy in children with trisomy 21.

Authors:  Karen R Rabin; James A Whitlock
Journal:  Oncologist       Date:  2009-01-28

Review 9.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

10.  Stability and change in health, functional abilities, and behavior problems among adults with and without Down syndrome.

Authors:  Anna J Esbensen; Marsha Mailick Seltzer; Marty Wyngaarden Krauss
Journal:  Am J Ment Retard       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.